iMeds.se

Nocdurna

Document: Nocdurna oral lyophilisate ENG PL change

Package leaflet: Information for the user


Nocdurna 25 microgram oral lyophilisate

Nocdurna 50 microgram oral lyophilisate


desmopressin


Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.


What is in this leaflet

1. What Nocdurna is and what it is used for

2. What you need to know before you take Nocdurna

3. How to take Nocdurna

4. Possible side effects

How to store Nocdurna

6. Contents of the pack and other information


What Nocdurna is and what it is used for


Nocdurna contains desmopressin , an antidiuretic, which reduces urine production.

Nocdurna is used for the treatment of nocturia (frequent need to get up to urinate at night) due to nocturnal polyuria (overproduction of urine during night) in adults.


What you need to know before you take Nocdurna


Do not take Nocdurna:


Warnings and precautions

Talk to your doctor or pharmacist before taking Nocdurna.


It is especially important that you talk to your doctor before taking Nocdurna if:


You must limit fluid intake to a minimum from 1 hour before taking Nocdurna until 8 hours after taking Nocdurna. Treatment without simultaneous reduction of fluid intake may lead to water retention and/or mineral imbalances with or without accompanying warning signs and symptoms hereunder such as headache, nausea/vomiting, weight gain and, in severe cases, convulsions.


Other medicines and Nocdurna

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.


It is especially important you tell it to your doctor if you are taking:


Nocdurna with foodand drink

Nocdurna should not be taken with food, since the effect may be reduced.


Pregnancy, breast-feeding and fertility

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.


Your doctor will decide if you can use this medicine during pregnancy or if you are breast-feeding.


Driving and using machines

Nocdurna has no or negligible influence on the ability to drive and use machines.


How to take Nocdurna


Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.


The recommended dose is


Nocdurna is placed under the tongue where it dissolves without the need for water.



Instructions for use

1. Completely remove the end tab of a blister strip by tearing along the perforations, starting from the corner with the hand symbol.

2. Now remove one blister from the strip by tearing along the perforations.

3. Remove the foil on each blister, starting at the corner with the printed arrow, by peeling off the foil in the direction of the arrow.Do not push the tablet through the foil.

4. Carefully take a tablet out of its blister. Place the tablet under the tongue and allow it to dissolve.Do not chew or swallow the tablet.

5. If a tablet breaks into more than two pieces while you are taking it out of its blister, do not take the broken pieces. Take a tablet from another blister.



You must limit fluid intake to a minimum from 1 hour before taking Nocdurna until 8 hours after taking Nocdurna. If you experience any of the following symptoms the treatment should be stopped and your doctor contacted: headache, nausea/vomiting, weight gain and, in severe cases, convulsions (see the section “Warnings and precautions” above). Your doctor can choose to restart treatment. When restarting treatment, you must strictly restrict fluid intake. In addition, your doctor will closely monitor the sodium levels in your blood.


Use in elderly patients (65 years of age and older)

If you are 65 years or older your doctor will have to monitor the level of sodium in your blood before starting the treatment, during the first week of treatment (4-8 days after initiation of the treatment) and again in about one month after the initiation of the treatment.


Kidney impairment

If you have moderately or severely reduced kidney function, do not take Nocdurna

Talk to your doctor.


Liver impairment

If you have impaired liver function you should talk to your doctor before taking Nocdurna.


Use in children and adolescents

This medicine is for use in adults only


If you take more Nocdurna than you should

It is important that you do not take more than the prescribed dose in any 24 hour period. Special attention should be given to signs of hyperhydration of the body (water intoxication), such as. weight gain, headache, nausea and, in severe cases, convulsions.

Please consult your doctor if you have taken more Nocdurna than you should.


If you forget to take Nocdurna

Do not take a double dose to make up for a forgotten tablet. Continue taking the tablets as usual on the next day.


If you stop taking Nocdurna

Treatment should only be interrupted or stopped on advice of your doctor.


If you have any further questions on the use of this medicine, ask your doctor or pharmacist.


4. Possible side effects


Like all medicines, this medicine can cause side effects, although not everybody gets them.


Drinking too much fluid may lead to a build up of water which dilutes the salt in the body in severe cases. This can become a serious problem and may lead to convulsions.


Stop taking this medicine and tell your doctor immediately or go to your nearest casualty department if you experience one or more of these symptoms,

- an unusually bad or prolonged headache,

- confusion,

- unexplained weight gain,

- nausea or vomiting.


Side Effects include:


Very common: may affect more than 1 in 10 people

Dry mouth


Common: may affect up to 1in 10 people


Uncommon: may affect up to 1 to 100 people


Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.


5. How to store Nocdurna


Keep this medicine out of the sight and reach of children.


This medicinal product does not require any special temperature storage conditions.

Store in the original package in order to protect from moisture and light.

Use immediately upon opening individual tablet blister.


Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.


Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.


6. Contents of the pack and other information


What Nocdurna contains


The active substance is desmopressin added as desmopressin acetate.

Each oral lyophilisate contains 25 microgram desmopressin.

Each oral lyophilisate contains 50 microgram desmopressin.


The other ingredients are gelatin, mannitol (E 421) and citric acid, anhydrous


What Nocdurna looks like and contents of the pack


Nocdurna 25 microgram:

White, round, oral lyophilisate tablet of approximately 12 mm marked with 25 on one side.


Nocdurna 50 microgram:

White, round, oral lyophilisate tablet of approximately 12 mm marked with 50 on one side.


Laminated aluminium blister sheets in an outer carton. Each perforated unit dose blister sheet contains 10 oral lyophilisates.

Pack size:

10x1, 30x1, 90x1 or 100x1 oral lyophilisates.


Not all pack sizes may be marketed.


Marketing Authorisation Holder and Manufacturer


<[To be completed nationally]>


<This medicinal product is authorised in the Member States of the EEA under the following names:>


<{Name of the Member State}> <{Name of the medicinal product}>

<{Name of the Member State}> <{Name of the medicinal product}>


This leaflet was last revised in 2016-04-21


5